Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + metoprolol
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Candesartan + metoprolol is a combination of two antihypertensive agents used together to manage high blood pressure and heart failure. Candesartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the type-1 angiotensin II receptor (AT1), inhibiting vasoconstriction and aldosterone secretion, which leads to decreased blood pressure[8]. Metoprolol is a beta-1 adrenergic receptor antagonist (beta-blocker) that reduces cardiac output by decreasing heart rate and contractility, thereby lowering blood pressure and reducing myocardial oxygen demand[4]. This combination targets different mechanisms in cardiovascular regulation, providing additive or synergistic effects for conditions such as hypertension and heart failure[2][5].
- Other names
- candesartan cilexetilmetoprolol tartratemetoprolol succinate
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ADRB1 (β1)
Beyond the preview
Go deeper on candesartan + metoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + metoprolol.